Similar articles

• Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation.

  Keown P, Balshaw R, Khorasheh S, Chong M, Marra C, Kalo Z, Korn A. Keown P, et al. BioDrugs. 2003;17(4):271-9. doi: 10.2165/00063030-200317040-00006. BioDrugs. 2003. PMID: 12899644
• [Toward an evidence-based immunosuppression].

  Pascual J. Pascual J. Nefrologia. 2001;21(6):524-5; discussion 526-7. Nefrologia. 2001. PMID: 11881421 Spanish. No abstract available.
• Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.

  Pescovitz MD, Govani M. Pescovitz MD, et al. Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S16-21. doi: 10.1053/ajkd.2001.27506. Am J Kidney Dis. 2001. PMID: 11583940 Review.
• Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.

  Lindenfeld J, Miller GG, Shakar SF, Zolty R, Lowes BD, Wolfel EE, Mestroni L, Page RL 2nd, Kobashigawa J. Lindenfeld J, et al. Circulation. 2004 Dec 21;110(25):3858-65. doi: 10.1161/01.CIR.0000150332.42276.69. Circulation. 2004. PMID: 15611389 Review. No abstract available.
• Switching immunosuppression medications after renal transplantation--a common practice.

  Meier-Kriesche HU, Chu AH, David KM, Chi-Burris K, Steffen BJ. Meier-Kriesche HU, et al. Nephrol Dial Transplant. 2006 Aug;21(8):2256-62. doi: 10.1093/ndt/gfl134. Epub 2006 Mar 30. Nephrol Dial Transplant. 2006. PMID: 16574677